Heron Therapeutics Inc. [NASDAQ: HRTX] plunged by -$0.2 during the normal trading session on Friday and reaching a high of $5.10 during the day while it closed the day at $4.67. The company report on September 16, 2022 that Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV).
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
– APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicatedfor PONV -.
– Delivered via a single 30-second IV injection, APONVIE has demonstrated rapid achievement of therapeutic drug levels ideally suited for the surgical setting -.
Heron Therapeutics Inc. stock has also loss -7.71% of its value over the past 7 days. However, HRTX stock has inclined by 79.62% in the 3 months of the year. Over the past six months meanwhile, it has lost -14.94% and lost -48.85% year-on date.
The market cap for HRTX stock reached $499.78 million, with 102.41 million shares outstanding and 102.39 million shares in the current float. Compared to the average trading volume of 3.11M shares, HRTX reached a trading volume of 21009927 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Heron Therapeutics Inc. [HRTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HRTX shares is $15.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HRTX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Heron Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 27, 2020. While these analysts kept the previous recommendation, Needham dropped their target price from $50 to $48. The new note on the price target was released on February 20, 2020, representing the official price target for Heron Therapeutics Inc. stock. Previously, the target price had yet another drop from $66 to $64, while Needham kept a Buy rating on HRTX stock.
The Average True Range (ATR) for Heron Therapeutics Inc. is set at 0.45, with the Price to Sales ratio for HRTX stock in the period of the last 12 months amounting to 5.26.
HRTX stock trade performance evaluation
Heron Therapeutics Inc. [HRTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.71. With this latest performance, HRTX shares dropped by -8.61% in over the last four-week period, additionally sinking by -14.94% over the last 6 months – not to mention a drop of -60.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HRTX stock in for the last two-week period is set at 54.83, with the RSI for the last a single of trading hit 53.25, and the three-weeks RSI is set at 55.51 for Heron Therapeutics Inc. [HRTX]. The present Moving Average for the last 50 days of trading for this stock 3.92, while it was recorded at 4.74 for the last single week of trading, and 5.58 for the last 200 days.
Heron Therapeutics Inc. [HRTX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Heron Therapeutics Inc. [HRTX] shares currently have an operating margin of -250.42 and a Gross Margin at +46.70. Heron Therapeutics Inc.’s Net Margin is presently recorded at -255.58.
Return on Equity for this stock declined to -140.53, with Return on Assets sitting at -66.95.
Heron Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.80.
Earnings per share (EPS) analysis for Heron Therapeutics Inc. [HRTX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HRTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Heron Therapeutics Inc. go to 47.50%.
Heron Therapeutics Inc. [HRTX]: Insider Ownership positions
There are presently around $539 million, in the hands of institutional investors. The top three institutional holders of HRTX stocks are: STATE STREET CORP with ownership of 16,328,796, which is approximately 26.351% of the company’s market cap and around 0.20% of the total institutional ownership; FRANKLIN RESOURCES INC, holding 11,831,524 shares of the stock with an approximate value of $55.25 million in HRTX stocks shares; and UBS OCONNOR LLC, currently with $47.38 million in HRTX stock with ownership of nearly 3.026% of the company’s market capitalization.
Positions in Heron Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 79 institutional holders increased their position in Heron Therapeutics Inc. [NASDAQ:HRTX] by around 11,339,805 shares. Additionally, 84 investors decreased positions by around 13,964,825 shares, while 46 investors held positions by with 90,198,975 shares. The mentioned changes placed institutional holdings at 115,503,605 shares, according to the latest SEC report filing. HRTX stock had 19 new institutional investments in for a total of 1,765,796 shares, while 28 institutional investors sold positions of 4,875,738 shares during the same period.